Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 1
2015 3
2016 1
2017 3
2018 5
2019 2
2020 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
[CME: Acquired Hemophagocytic Lymphohistiocytosis].
Leinenkugel G, Buser L, Vallelian F, Herfs G. Leinenkugel G, et al. Among authors: buser l. Praxis (Bern 1994). 2018 Aug;107(16):873-881. doi: 10.1024/1661-8157/a003040. Praxis (Bern 1994). 2018. PMID: 30086677 Review. German.
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W. Dai X, et al. Among authors: buser l. Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14. Nat Med. 2017. PMID: 28805820 Free PMC article.
Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.
Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S. Erichsen L, et al. Among authors: buser l. Sci Rep. 2018 Feb 22;8(1):3477. doi: 10.1038/s41598-018-21932-7. Sci Rep. 2018. PMID: 29472622 Free PMC article.
Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.
Meyer S, Buser L, Haferkamp S, Berneburg M, Maisch T, Klinkhammer-Schalke M, Pauer A, Vogt T, Garbe C. Meyer S, et al. Among authors: buser l. Eur J Cancer. 2023 Mar;182:77-86. doi: 10.1016/j.ejca.2023.01.002. Epub 2023 Jan 7. Eur J Cancer. 2023. PMID: 36753835 Free article.
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Voskuilen CS, Oo HZ, Genitsch V, Smit LA, Vidal A, Meneses M, Necchi A, Colecchia M, Xylinas E, Fontugne J, Sibony M, Rouprêt M, Lenfant L, Côté JF, Buser L, Saba K, Furrer MA, van der Heijden MS, Daugaard M, Black PC, van Rhijn BWG, Hendricksen K, Poyet C, Seiler R. Voskuilen CS, et al. Among authors: buser l. Am J Surg Pathol. 2019 Dec;43(12):1600-1610. doi: 10.1097/PAS.0000000000001371. Am J Surg Pathol. 2019. PMID: 31524642 Free article.
22 results